Abbvie Inc.

Christopher Chumsae

Xiaobei Zeng

Kartik Subramanian

Hong Yang

Natarajan Ramasubramanyan

Matthew Omon Herigstad

Lihua Yang

Diane D Dong

Wen Chung Lim

Kathreen A Gifford

Zehra Kaymakcalan

Chee Furng Wong

Mayda Perez Thiele

Ying Jing

Mayda Perez

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.

Protein purification methods to reduce acidic species

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.

Methods to modulate lysine variant distribution

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations.

Cell culture methods to reduce acidic species

The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF&#x3b1; is detrimental, are also provided.

Low acidic species compositions and methods for producing and using the same

Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.

Human antibodies that bind human TNF-alpha and methods of preparing the same

The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF&#x3b1; is detrimental, are also provided.

Modulated lysine variant species compositions and methods for producing and using the same

Low acidic species compositions

Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.

Growing community of inventors

North Andover, MA, United States of America

Christopher Chumsae